Cited by 713Statistical Methods in Clinical TrialsColorectal Cancer Treatments and StudiesColorectal Cancer Surgical Treatments

The DOI matches its Crossref record; 33 of the 34 references it cites were found in a registry or an index.

Disease-Free Survival Versus Overall Survival As a Primary End Point for Adjuvant Colon Cancer Studies: Individual Patient Data From 20,898 Patients on 18 Randomized Trials

Sargent, Daniel J., Wieand, Harry S., Haller, Daniel G., Gray, Richard, Benedetti, Jacqueline K., Buyse, Marc, Labianca, Roberto, Seitz, Jean Francois, O'Callaghan, Christopher J., Francini, Guido, Grothey, Axel, O'Connell, Michael, Catalano, Paul J., Blanke, Charles D., Kerr, David, Green, Erin, Wolmark, Norman, Andre, Thierry, Goldberg, Richard M., De Gramont, Aimery·2005·Journal of Clinical Oncology

DOI 10.1200/jco.2005.01.6071

Open this paper in CoChat — free account

Abstract

PURPOSE: A traditional end point for colon adjuvant clinical trials is overall survival (OS), with 5 years demonstrating adequate follow-up. A shorter-term end point providing convincing evidence to allow treatment comparisons could significantly speed the translation of advances into practice. METHODS: Individual patient data were pooled from 18 randomized phase III colon cancer adjuvant clinical trials. Trials included 43 arms, with a pooled sample size of 20,898 patients. The primary hypothesis was that disease-free survival (DFS), with 3 years of follow-up, is an appropriate primary end point to replace OS with 5 years of follow-up. RESULTS: The recurrence rates for years 1 through 5 were 12%, 14%, 8%, 5%, and 3%, respectively. Median time from recurrence to death was 12 months. Eighty percent of recurrences were in the first 3 years; 91% of patients with recurrence by 3 years died before 5 years. Correlation between 3-year DFS and 5-year OS was 0.89. Comparing control versus experimental arms within each trial, the correlation between hazard ratios for DFS and OS was 0.92. Within-trial log-rank testing using both DFS and OS provided the same conclusion in 23 (92%) of 25 cases. Formal measures of surrogacy were satisfied. CONCLUSION: In patients treated on phase III adjuvant colon clinical trials, DFS and OS are highly correlated, both within patients and across trials. These results suggest that DFS after 3 years of median follow-up is an appropriate end point for adjuvant colon cancer clinical trials of fluorouracil-based regimens, although marginally significant DFS improvements may not translate into significant OS benefits.

Integrity signals

Registry

Crossref · 10.1200/jco.2005.01.6071

Cites

33 of 33 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Regression Models and Life-Tables
Cox, D. R. (1972) · Journal of the Royal Statistical Society Series B: Statistical Methodology · doi:10.1111/j.2517-6161.1972.tb00899.x · Cited by 39,793
Bevacizumab plus Irinotecan, Fluorouracil, and Leucovorin for Metastatic Colorectal Cancer
Hurwitz, H., Fehrenbacher, L., Novotny, W., Cartwright, T., Hainsworth, J., Heim, W., Berlin, J., Baron, A., Griffing, S., Holmgren, E., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa032691 · Cited by 10,968
Oxaliplatin, Fluorouracil, and Leucovorin as Adjuvant Treatment for Colon Cancer
André, T., Boni, C., Mounedji-Boudiaf, L., Navarro, M., Tabernero, J. M., Hickish, T., Topham, C., Zaninelli, M., Clingan, P. R., Bridgewater, J. A., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa032709 · Cited by 3,694
A leisurely look at the bootstrap, the jackknife, and cross-validation
Efron, B., & Gong, G. (1983) · The American Statistician · doi:10.1080/00031305.1983.10483087 · Cited by 3,229
Irinotecan plus Fluorouracil and Leucovorin for Metastatic Colorectal Cancer
Saltz, L. B., Cox, J. V., Blanke, C. D., Rosen, L. S., Fehrenbacher, L., Moore, M. J., Maroun, J. A., Ackland, S. P., Locker, P. K., Pirotta, N., et al. (2000) · New England Journal of Medicine · doi:10.1056/nejm200009283431302 · Cited by 3,004
Levamisole and Fluorouracil for Adjuvant Therapy of Resected Colon Carcinoma
Moertel, C. G., Fleming, T. R., Macdonald, J. S., Haller, D. G., Laurie, J. A., Goodman, P. J., Ungerleider, J. S., Emerson, W. A., Tormey, D. C., Glick, J. H., et al. (1990) · New England Journal of Medicine · doi:10.1056/nejm199002083220602 · Cited by 2,261
A Randomized Controlled Trial of Fluorouracil Plus Leucovorin, Irinotecan, and Oxaliplatin Combinations in Patients With Previously Untreated Metastatic Colorectal Cancer
Goldberg, R. M., Sargent, D. J., Morton, R. F., Fuchs, C. S., Ramanathan, R. K., Williamson, S. K., Findlay, B., Pitot, H. C., & Alberts, S. R. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2004.09.046 · Cited by 2,251
Surrogate endpoints in clinical trials: Definition and operational criteria
Prentice, R. L. (1989) · Statistics in Medicine · doi:10.1002/sim.4780080407 · Cited by 2,057
Surrogate End Points in Clinical Trials: Are We Being Misled?
Fleming, T. R., & DeMets, D. L. (1996) · Annals of Internal Medicine · doi:10.7326/0003-4819-125-7-199610010-00011 · Cited by 1,651
American Society of Clinical Oncology Recommendations on Adjuvant Chemotherapy for Stage II Colon Cancer
Benson, A. B., Schrag, D., Somerfield, M. R., Cohen, A. M., Figueredo, A. T., Flynn, P. J., Krzyzanowska, M. K., Maroun, J. A., McAllister, P. K., Cutsem, E. V., et al. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.05.063 · Cited by 1,438

Flagged first, then by citations

Show all 34 references

1 of the 34 references couldn’t be matched to a known paper.

Sorted by citations

Items 501–600 of 713

Matted Lymph Nodes on MRI in Nasopharyngeal Carcinoma: Prognostic Factor and Potential Indication for Induction Chemotherapy Benefits
Dong, A., Zhu, S., Ma, H., Wei, X., Huang, W., Ruan, G., Liu, L., Mo, Y., & Ai, F. (2023) · Journal of Magnetic Resonance Imaging · doi:10.1002/jmri.29012 · Cited by 5
“25,26 If con ﬁ rmed by biopsy pathology or determined through imaging methods, it is recorded as a metastasis.”
Background
Recurrence-Free Survival as a Surrogate for Overall Survival Among Patients with Intrahepatic Cholangiocarcinoma Following Upfront Surgery: An International Multi-institutional Analysis
Kawashima, J., Endo, Y., Woldesenbet, S., Khalil, M., Akabane, M., Cauchy, F., Shen, F., Maithel, S. K., Popescu, I., Kitago, M., et al. (2025) · Annals of Surgical Oncology · doi:10.1245/s10434-025-17156-5 · Cited by 5
“12 These analyses established that 3-year RFS could serve as a surrogate for 5-year OS.”
Influential
Colorectal Cancer
Schaeybroeck, S. V., Lawler, M., Johnston, B. T., Salto‐Tellez, M., Lee, J., Loughlin, P., Wilson, R. H., & Johnston, P. G. (2014) · Elsevier eBooks · doi:10.1016/b978-1-4557-2865-7.00077-1 · Cited by 5
Association Between Event-Free Survival and Overall Survival in Early-Stage Triple-Negative Breast Cancer
Huang, M., Fasching, P. A., Haiderali, A., Xue, W., Pan, W., Karantza, V., Yang, F., Truscott, J., Xin, Y., & O’Shaughnessy, J. (2023) · Future Oncology · doi:10.2217/fon-2023-0315 · Cited by 5
Assessing Cancer Drugs for Reimbursement: Methodology, Relationship between Effect Size and Medical Need
de Sahb-Berkovitch, R., Woronoff-Lemsi, M.-C., Molimard, M., Armand, J., Bardou, M., Bergougnoux, L., Bouchet, C., Cellier, D., Dahmani, B., Diquet, B., et al. (2010) · Therapies · doi:10.2515/therapie/2010042 · Cited by 5
“[8–11] In nonvalidated cases such as breast cancer, PFS is considered an intermediate endpoint.”
Background
Cost-Effectiveness Analysis of Adjuvant Stage III Colon Cancer Treatment at Veterans Affairs Medical Centers
Soni, A., Aspinall, S. L., Zhao, X., Good, C. B., Cunningham, F. E., Chatta, G. S., Passero, V. A., & Smith, K. J. (2015) · Oncology Research Featuring Preclinical and Clinical Cancer Therapeutics · doi:10.3727/096504015x14424348426152 · Cited by 5
Merkel Cell Carcinoma: Changing Practice Patterns and Impact on Recurrence-Free and Overall Survival at a Single Institution and Nationally
Esposito, A. C., Jacobs, D., Ariyan, S., Galan, A., Kluger, H. M., Clune, J. E., Weiss, S. A., Tran, T. T. T., & Olino, K. L. (2021) · Annals of Surgical Oncology · doi:10.1245/s10434-021-10727-2 · Cited by 5
Developments in combination chemotherapy for colorectal cancer
Goetz, M. P., & Grothey, A. A. (2004) · Expert Review of Anticancer Therapy · doi:10.1586/14737140.4.4.627 · Cited by 5
New strategies in colon cancer adjuvant therapy
Labianca, R., Mosconi, S., & Garassino, M. C. (2006) · Annals of Oncology · doi:10.1093/annonc/mdl951 · Cited by 5
“From a methodological point of view [10, 11], 3-year DFS seems to be a good surrogate end point for 5-year overall survival (OS) after Sargent’s analysis of 15 international trials.”
Background
Progression‐free survival: Does a correlation with survival justify its role as a surrogate clinical endpoint?
Becker, A., Eichelberg, C., & Sun, M. (2013) · Cancer · doi:10.1002/cncr.28378 · Cited by 5
“Recently, an increasing number of clinical trials not limited to metastatic kidney cancer have focused on PFS as the primary endpoint instead of the previously established standard clinical endpoint of OS.(15-18) In fact, according to a review”
Background
Guides for adjuvant treatment of colon cancer
Aranda, E., Abad, A., Carrato, A., Cervantes, A. M. R., Tabernero, J. M., & Díaz‐Rubio, E. (2006) · Clinical & Translational Oncology · doi:10.1007/s12094-006-0165-y · Cited by 5
Don't forget survival, please…
Perrone, F. (2006) · The Lancet Oncology · doi:10.1016/s1470-2045(06)70839-7 · Cited by 5
Reply to H. Wong et al
Sanoff, H. K., Carpenter, W. R., Stürmer‎, T., & Schrag, D. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2012.46.4859 · Cited by 5
Prognostic and predictive factors in colorectal cancer
Derwinger, K. (2009) · Gothenburg University Publications Electronic Archive (Gothenburg University) · Cited by 5
Big Data, Small Effects
Höchster, H. S., & Niedzwiecki, D. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2015.65.8161 · Cited by 5
“The ACCENT group has published extensively on important topics relevant to patient care and clinical trials design.2 The most important work coming out of this collaboration is the demonstration that 3-year disease-free survival is predictive of 5-year overall survival and the acceptance of this earlier end point by t…”
Background
Topological Summaries of Tumor Images Improve Prediction of Disease Free Survival in Glioblastoma MultiformePreprint
Crawford, L. A., Monod, A., Chen, A., Mukherjee, S., & Rabadán, R. (2016) · arXiv (Cornell University) · Cited by 5
Shedding Light on the Prognostic and Predictive Value of Circulating Tumor DNA for Management of Patients with Early-Stage Colon Cancer
Yanes, R. B., Saridogan, T., Gorantla, V. C., Overacre-Delgoffe, A. E., Hsieh, R. W., Celebrezze, J. P., Magge, T., Singh, M., Saeed, A., Zureikat, A. H., et al. (2025) · Technology in Cancer Research & Treatment · doi:10.1177/15330338251317094 · Cited by 4
Novel and Simple Nomograms Using Inflammation and Nutritional Biomarkers for Stage II–III Colon Cancer, Taking “Time after Curative Surgery” into Consideration
Mazaki, J., Katsumata, K., Tago, T., Kasahara, K., Enomoto, M., Ishizaki, T., Nagakawa, Y., & Tsuchida, A. (2022) · Nutrition and Cancer · doi:10.1080/01635581.2022.2042570 · Cited by 4
Study on the Expression Profile of Autophagy-Related Genes in Colon Adenocarcinoma
Hou, M., Ma, J., & Ma, J. (2022) · Computational and Mathematical Methods in Medicine · doi:10.1155/2022/7525048 · Cited by 4
“Colon cancer has a high recurrence rate after treatment, 42% of patients will relapse within 5 years, and the median time from recurrence to death is 12 months [3].”
Background
Correlation between pathologic complete response, event-free survival/disease-free survival and overall survival in neoadjuvant and/or adjuvant HR+/HER2-breast cancer
Gogate, A., Ranjan, S., Kumar, A., Bhandari, H., Papademetriou, E., Kim, I., & Potluri, R. C. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1119102 · Cited by 4
Inflammation, physical activity, and disease-free survival in stage III colon cancer: Cancer and Leukemia Group B–Southwest Oncology Group 80702 (Alliance)
Brown, J. C., Ma, C., Shi, Q., Couture, F., Kuebler, P. J., Kumar, P., Tan, B. R., Krishnamurthi, S., Chang, V. T.-S., Goldberg, R. M., et al. (2024) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djae203 · Cited by 6
“Absolute effects are presented as risk differences at 3 years for disease-free survival and 5 years for overall survival, as these time horizons are clinically meaningful (21).”
Correlation analysis of invasive disease‐free survival and overall survival in a real‐world population of patients with HR+/HER2– early breast cancer
Graff, S. L., Tolaney, S. M., Hart, L. L., Razavi, P., Janni, W. J., Schwartzberg, L. S., Danyliv, A., Akdere, M., Ferrusi, I. L., Adhikary, R. R., et al. (2025) · Cancer · doi:10.1002/cncr.35817 · Cited by 4
“8,9,25,26 Additionally, a meta - analysis of RCTs in HER2 þ EBC demonstrated patient - level correlation between DFS and OS, with a Spearman coefficient of0.”
Transient Carcinoembryonic Antigen Elevations During Adjuvant Chemotherapy for Colorectal Cancer Reflect the Burden of Residual Micrometastatic Disease
Yau, T. C. C., Wong, H., Chan, P., Chan, T., Mak, J. W. Y., & Epstein, R. J. (2010) · Clinical Colorectal Cancer · doi:10.3816/ccc.2010.n.015 · Cited by 4
Clinically Relevant Study End Points in Rectal Cancer
Fernández-Martos, C., Guerrero, Á., & Minsky, B. D. (2012) · Recent results in cancer research/Recent Results in Cancer Research · doi:10.1007/978-3-642-31629-6_1 · Cited by 4
Addition of platinum derivatives to neoadjuvant single-agent fluoropyrimidine chemoradiotherapy in patients with stage II/III rectal cancer: protocol for a systematic review and meta-analysis (PROSPERO CRD42017073064)
Hüttner, F. J., Probst, P., Kalkum, E., Hackbusch, M., Jensen, K., Ulrich, A. B., Büchler, M. W., & Diener, M. K. (2018) · Systematic Reviews · doi:10.1186/s13643-018-0678-9 · Cited by 4
“However, for colorectal cancer, disease-free survival has been shown to correlate well with overall survival [33].”
Background
Statistical Considerations for Trials in Adjuvant Treatment of Colorectal Cancer
Saad, E. D., & Buyse, M. E. (2020) · Cancers · doi:10.3390/cancers12113442 · Cited by 5
“Colon cancer has spearheaded the search for validated surrogate endpoints that could replace OS in phase 3 trials [33,35,36].”
BackgroundMethodInfluential
End of induction positron emission tomography complete response (PET‐CR) as a surrogate for progression‐free survival in previously untreated follicular lymphoma
Dixon, J. G., Dimier, N., Nielsen, T. G., Zheng, J., Marcus, R. E., Morschhauser, F., Evens, A. M., Federico, M., Blum, K. A., & Shi, Q. (2022) · British Journal of Haematology · doi:10.1111/bjh.18217 · Cited by 4
Assessment of Attitudes Toward Initiation of Immediate Adjuvant Chemotherapy for Colon Cancer
Mesiti, A. M., Brouwer, J., Jafari, M. D., Qiu, Y., Wenzel, L. B., Carmichael, J. C., McKinney, C. O., Zell, J. A., & Pigazzi, A. (2022) · Journal of Surgical Research · doi:10.1016/j.jss.2022.11.024 · Cited by 4
Locally Advanced Rectal Cancer Patients Receiving Radio-Chemotherapy: A Novel Clinical–Pathologic Score Correlates With Global Outcome
Berardi, R., Mantello, G., Scartozzi, M., Prete, S. D., Luppi, G., Martinelli, R., Fumagalli, M., Ruggieri, F. G., Bearzi, I., Mandolesi, A., et al. (2009) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2009.01.016 · Cited by 4
Failure of bevacizumab in early-stage colon cancer
Sargent, D. J. (2010) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2010.205 · Cited by 4
Yield of Routine Imaging after Curative Colorectal Cancer Treatment
Jochmans, I., Topal, B., D’Hoore, A. J. L., Aerts, R., Vanbeckevoort, D., Bielen, D., Haustermans, K. M., Cutsem, E. V., & PENNINCKX, F. M. (2008) · Acta chirurgica Belgica · doi:10.1080/00015458.2008.11680182 · Cited by 4
Adjuvant Chemotherapy for Colon Cancer
O’Neil, B. H., Kelly, H., Morse, M. A., & Goldberg, R. M. (2007) · Humana Press eBooks · doi:10.1007/978-1-59745-215-1_8 · Cited by 4
Introduction to Clinical Trials
Goffin, J. R. (2010) · Pharmaceutical Sciences Encyclopedia · doi:10.1002/9780470571224.pse200 · Cited by 4
Management of colorectal cancer in older adults: an expert panel recommendation to guide daily clinical practice
Liposits, G. I., André, T., Aparicio, T., Montroni, I., Taı̈eb, J., Gallois, C., Cutsem, E. V., Ducreux, M. P., Pfeiffer, P., Lonardi, S., et al. (2026) · The Lancet. Gastroenterology & hepatology · doi:10.1016/s2468-1253(26)00041-5 · Cited by 3
Splenomegaly in Colon Cancer During Adjuvant Oxaliplatin-based Chemotherapy
Eren, T., & Paşaoğlu, L. (2020) · Cureus · doi:10.7759/cureus.7230 · Cited by 3
NCCN Guideline Concordance Improves Survival in Pediatric and Young Adult Rectal Cancer
Nofi, C. P., Siskind, S., Deutsch, G. B., Ricci, J. P., & Lipskar, A. M. (2023) · Journal of Pediatric Surgery · doi:10.1016/j.jpedsurg.2023.09.042 · Cited by 3
Colon Cancer
Desouza, A. L., Nadkarni, S., Roy, S., Kataria, P., Ramaswamy, A., & Ostwal, V. S. (2024) · Springer eBooks · doi:10.1007/978-981-99-3378-5_40 · Cited by 3
Targeted Therapies as Adjuvant Treatment for Early-Stage Colorectal Cancer: First Impressions and Clinical Questions
Banerjee, S. N., & Cunningham, D. (2010) · Clinical Colorectal Cancer · doi:10.3816/ccc.2010.s.004 · Cited by 3
Surrogate endpoint for overall survival in assessment of adjuvant therapies after curative treatment for hepatocellular carcinoma: a re-analysis of meta-analyses of individual patients’ data
Huan, H.-B., Wu, L., Lau, W. Y., Wen, X.-D., Zhang, L., Yang, D., Wang, X.-S., Bie, P., & Xia, F. (2017) · Oncotarget · doi:10.18632/oncotarget.18853 · Cited by 3
“OS was defined as the time from randomization to death from any cause [14].”
Background
Final analyses of the prospective controlled trial on the efficacy of uracil and tegafur/leucovorin as an adjuvant treatment for stage II colon cancer with risk factors for recurrence using propensity score-based methods (JFMC46-1201)
Ogata, Y., Sadahiro, S., Sakamoto, K., Tsuchiya, T., Takahashi, T., Ohge, H., Satō, T., Kondo, K., Baba, H. A., Itabashi, M., et al. (2024) · International Journal of Clinical Oncology · doi:10.1007/s10147-024-02565-5 · Cited by 3
“…before the approval of oxaliplatin and irinotecan for advanced disease, demonstrated that 3-year DFS is an excellent predictor of 5-year OS [22] and could be an appropriate primary endpoint for adjuvant studies in CC. Based on these findings, 3-year DFS was recognized by the US Food and…”
Improved quality of colon cancer surveillance after implementation of a personalized surveillance schedule
Rueff, J., Weixler, B., Viehl, C. T., Ochsner, A., Warschkow, R., Güller, U., Mingrone, W. B., & Zuber, M. (2020) · Journal of Surgical Oncology · doi:10.1002/jso.25973 · Cited by 3
“3‐5 Most disease recurrences (80%) occur within the first 3 years after initial surgical resection.(6) On the other side, due to steadily improving treatment strategies 5‐year survival rates of patients with disease recurrence are nowadays approaching 40%.”
Background
Projecting Event-Based Analysis Dates in Clinical Trials: An Illustration Based on the International Duration Evaluation of Adjuvant Chemotherapy (IDEA) Collaboration. Projecting Analysis Dates for the IDEA Collaboration
Renfro, L. A., Grothey, A., Paul, J., Floriani, I., Bonnetain, F., Niedzwiecki, D., Yamanaka, T., Souglakos, I., Yothers, G., & Sargent, D. J. (2014) · Forum of Clinical Oncology · doi:10.2478/fco-2014-0006 · Cited by 3
Increasing utilization and predictors of hematopoietic growth factors in patients diagnosed with colorectal cancer: findings from a large national population-based cohort in the USA, 1992–2009
Zhang, Y., Fu, S., & Du, X. L. (2014) · Medical Oncology · doi:10.1007/s12032-014-0242-y · Cited by 3
Potential surrogate endpoints in cancer research – some considerations and examples
Duffy, S. W., & Treasure, P. (2009) · Pharmaceutical Statistics · doi:10.1002/pst.406 · Cited by 3
End points for Phase II trials in recurrent glioblastoma: the cornerstone for a new era
Franceschi, E., Agati, R., & Brandes, A. A. (2011) · Expert Review of Anticancer Therapy · doi:10.1586/era.11.164 · Cited by 3
Critères et méthodologie d’évaluation au remboursement des anticancéreux
de Sahb-Berkovitch, R., Woronoff-Lemsi, M.-C., Molimard, M., Armand, J., Bardou, M., Bergougnoux, L., Bouchet, C., Cellier, D., Dahmani, B., Diquet, B., et al. (2010) · Therapies · doi:10.2515/therapie/20010041 · Cited by 3
“[8–11] Dans les cas non validés comme le cancer du sein, la PFS est considérée comme un critère intermédiaire.”
The effect of laparoscopic surgery in stage II and III right-sided colon cancer: a retrospective study
Kye, B., Kim, J.-G., Cho, H., Lee, J. H., Kim, H. J., Suh, Y. J., & Chun, C. (2012) · World Journal of Surgical Oncology · doi:10.1186/1477-7819-10-89 · Cited by 3
“The survival of patients with stage II and III colon cancer has increased with the increased number of lymph nodes examined [11].”
Background
Maximizing Return on Investment in Phase II Proof-of-Concept Trials
Chen, C., Beckman, R. A., & Sun, L. (2014) · Springer eBooks · doi:10.1007/978-3-319-09075-7_9 · Cited by 3
Adjuvant Chemotherapy in Older Adults With Colon Cancer
Williams, G. R., & Sanoff, H. K. (2015) · American Journal of Hematology / Oncology® · Cited by 3
Surrogate endpoints in head and neck cancer
Chen, L. L., & Cohen, E. E. W. (2009) · The Lancet Oncology · doi:10.1016/s1470-2045(09)70044-0 · Cited by 3
Comprehensive analysis of Distal-Less homeobox family gene expression in colon cancerPreprint
Chen, Y., Li, D., Wang, D., & Peng, H. (2022) · Research Square · doi:10.21203/rs.3.rs-1723161/v1 · Cited by 3
Mental illness and non-metastatic colorectal cancer treatment and survival, a nationwide study of almost 70,000 patients
Osterman, E., Syriopoulou, E., Martling, A., Andersson, T., & Nordenvall, C. A. M. (2025) · Acta Oncologica · doi:10.2340/1651-226x.2025.42710 · Cited by 2
“Most recurrences occur early [23], and as there was no statistically significant difference in TTR, the worse prognosis could be explained by worse SAR.”
The impact of lymph node harvest on recurrence in rectal cancer after neoadjuvant chemoradiotherapy
Jo, M. H., Kim, D., Lee, J. A., Choi, M. J., Shin, H.-R., Lee, T.-G., Ahn, H., Oh, H., Kang, S., Kim, M. J., et al. (2026) · Journal of Gastrointestinal Surgery · doi:10.1016/j.gassur.2026.102447 · Cited by 2
Colon Cancer in Elderly Patients: What is the Best Treatment?
Pasetto, L. M., Jirillo, A., Lonardi, S., Falci, C., & Monfardini, S. (2008) · Aging Health · doi:10.2217/1745509x.4.3.279 · Cited by 2
Stage III Colon Cancer: What Works, What Doesn't and Why, and What's Next
André, T., O’Neil, B. H., & Meyerhardt, J. A. (2012) · American Society of Clinical Oncology Educational Book · doi:10.14694/edbook_am.2012.32.39 · Cited by 2
Clinical Trial Methodology in Lung Cancer
Mandrekar, S. J., Redman, M. W., & Billingham, L. J. (2018) · Elsevier eBooks · doi:10.1016/b978-0-323-52357-8.00059-7 · Cited by 2
Impact of adjuvant chemotherapy on long-term overall survival in patients with high-risk stage II colon cancer: a nationwide cohort study
Rosberg, V., Jessen, M., Qvortrup, C., Smith, H. G., & Krarup, P. (2023) · Acta Oncologica · doi:10.1080/0284186x.2023.2251086 · Cited by 4
Predicting disease-free survival following curative-intent resection of right-sided colon cancer using a pre- and post-operative nomogram: a prospective observational cohort study
Lucocq, J. E., Trinder, T., Homyer, K., Baig, H. Z., Patil, P., & Muthukumarasamy, G. (2025) · International Journal of Surgery · doi:10.1097/js9.0000000000002300 · Cited by 2
“We adhered to the AJCC criteria for developing risk models during the development of our risk model [ 8 ] .”
Findings from the Adjuvant Colon Cancer End Points (ACCENT) Collaborative Group: the Power of Pooled Individual Patient Data from Multiple Clinical Trials
Shi, Q., Sargent, D. J., & Renfro, L. A. (2016) · Current Colorectal Cancer Reports · doi:10.1007/s11888-016-0331-8 · Cited by 2
“At this juncture, 6 more trials from NCCTG and the National Surgical Adjuvant Breast and Bowel Project (NSABP) were contributed to ACCENT, followed by 5 trials from other groups, resulting in ACCENT’s initial set of 18 trials studying adjuvant chemotherapy (1) (Table 1).”
Method
Composite endpoint analysis for assessing surrogacy with censored data
Ghosh, D. (2008) · International Conference on Bioinformatics · Cited by 2
Adding oxaliplatin to the equation
Benson, A. B. (2009) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2009.162 · Cited by 2
“Moreover, based on these findings, this concept was endorsed by the FDA”
Adjuvant and Palliative Chemotherapy for Colon Cancer in the Elderly Patient
Power, D. G., & Lichtman, S. M. (2008) · Seminars in Colon and Rectal Surgery · doi:10.1053/j.scrs.2008.09.009 · Cited by 2
Long-term Follow-up of Patients with Curatively Resected Colorectal Cancer; May Long-term Follow-up of More than 5 Years be Warranted?
Moon, S. M., Park, J. W., & Hwang, D. (2007) · Journal of the Korean Society of Coloproctology · doi:10.3393/jksc.2007.23.4.262 · Cited by 2
Timeliness of Care
Etzioni, D. A. (2011) · Seminars in Colon and Rectal Surgery · doi:10.1053/j.scrs.2011.06.006 · Cited by 2
Lack of generalizability of sensitivity and specificity with treatment effects
Dodd, L. E., & Korn, E. L. (2007) · Statistics in Medicine · doi:10.1002/sim.3101 · Cited by 2
Desenlaces clínicos en hematoncología: diez años de investigaciones en Pubmed
Rosselli, D., Diaz-Castrillon, C. E., & Gutiérrez, L. (2015) · Revista Colombiana de Cancerología · doi:10.1016/j.rccan.2015.02.002 · Cited by 2
Multispectral texture analysis of histopathological abnormalities in colorectal tissues
Chaddad, A., Desrosiers, C., Hassan, L., & Toews, M. (2016) · Proceedings - International Conference on Image Processing · doi:10.1109/icip.2016.7532835 · Cited by 2
Statistics and Clinical Trials
Wu, W., & Sargent, D. J. (2012) · Elsevier eBooks · doi:10.1016/b978-1-4377-1637-5.00012-2 · Cited by 2
A phase 1 dose-escalation and dose-expansion study to assess the safety and efficacy of CKD-516, a novel vascular disrupting agent, in combination with Irinotecan in patients with previously treated metastatic colorectal cancer
Jeong, H., Hong, Y. S., Kim, J. E., Lim, H.-S., Ahn, J. B., Shin, S. J., Park, Y. S., Kim, S. T., Han, S., Kim, T., et al. (2021) · Investigational New Drugs · doi:10.1007/s10637-021-01110-9 · Cited by 3
Hyaluronic Acid May Be a Predictive Biomarker for Thrombocytopenia and Liver Dysfunction After Oxaliplatin-based Chemotherapy
Miyata, T., Tomita, Y., Sannomiya, Y., Nagayama, T., Kin, R., Nishiki, H., Hashimoto, A., Fujii, Y., Miura, S., Kaida, D., et al. (2022) · Cancer Diagnosis & Prognosis · doi:10.21873/cdp.10071 · Cited by 2
Disease-free survival as the endpoint in multimodal rectal cancer trials: have we got this right?
Fokas, E., Rödel, C. M., Smith, J. J., García‐Aguilar, J., Buyse, M. E., & Glynne‐Jones, R. (2023) · The Lancet. Gastroenterology & hepatology · doi:10.1016/s2468-1253(23)00231-5 · Cited by 2
Neoadjuvant chemotherapy for locally advanced colonic cancer is not ready to be the standard of care
Vimalachandran, D. (2023) · British journal of surgery · doi:10.1093/bjs/znad184 · Cited by 2
The Role and Potential of Surrogate Outcomes in Clinical Trials: Have We Made Any Progress in the Past Decade?
DeMets, D. L. (2012) · Lecture notes in statistics · doi:10.1007/978-1-4614-5245-4_1 · Cited by 2
Molekulare Targets beim Kolonkarzinom
Röcken, C. (2008) · Der Pathologe · doi:10.1007/s00292-008-1041-z · Cited by 2
Laparoskopische kolorektale Tumorchirurgie
Spatz, H., Geißler, B., Paschwitz, R., & Anthuber, M. (2011) · Viszeralmedizin · doi:10.1159/000334985 · Cited by 2
Temsirolimus: Is Improved Survival the Correct Expression of Drug Activity?
Basso, M., Cassano, A., Schinzari, G., & Barone, C. A. (2010) · The Oncologist · doi:10.1634/theoncologist.2010-0099 · Cited by 2
Stage II Disease, Elderly Patients, Secondary Neoplasms, and the MOSAIC Trial
Gallén, M., Gallego, R., & Joaquim Bellmunt, B. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.47.1854 · Cited by 2
The big, the bad, and the exon 11: adjuvant imatinib for all gastro-intestinal stromal tumors or just the ugly?
Groisberg, R., & Subbiah, V. (2017) · Translational Gastroenterology and Hepatology · doi:10.21037/tgh.2017.09.10 · Cited by 2
“This has been validated in colon cancer as an acceptable surrogate marker (7), but the applicability to GIST is not clear.”
Background
Interpreting the RAPIDO trial: factors to consider
Yuval, J. B., Patil, S. N., & García‐Aguilar, J. (2021) · The Lancet Oncology · doi:10.1016/s1470-2045(21)00061-9 · Cited by 2
Surrogate Endpoints in Drug Development: A Review of Statistical and Regulatory Perspectives and Applications
Chen, T., Tian, Y., & Millen, B. A. (2025) · Wiley Interdisciplinary Reviews Computational Statistics · doi:10.1002/wics.70014 · Cited by 1
“For example, Sargent et al. (2005) conducted a meta-analysis of 18 randomized controlled trials in adjuvant colon cancer and observed a very high group-level correlation be-tween DFS and OS (Figure 1).”
Adjuvant Anti-Inflammatory Therapy in Postoperative Colorectal Cancer: A Systematic Review and Meta-analysis of Randomized Controlled Trials
Lenz, G., Pereira, R. A., Valagni, G., & Castria, T. B. D. (2025) · Clinical Colorectal Cancer · doi:10.1016/j.clcc.2025.08.003 · Cited by 1
Multi-Omics-Based Subtyping of Ovarian Cancer Using Deep Learning and SVM Classification
Hozain, E., & Badr, E. (2025) · Intelligent Methods, Systems, and Applications (IMSA) · doi:10.1109/imsa65733.2025.11166936 · Cited by 1
“Second, disease-403 free survival (DFS), the amount of time the patient lives from the day of treatment initiation to the occurrence of the first tumor recurrence in the same organ [60].”
Robotic versus laparoscopic surgery for middle and low rectal cancer: a retrospective cohort study emulating the target trial
Wang, K., Guo, T., Yu, M., Liu, K., Zhou, L., Gao, Y., Liang, F., Xu, J., & Feng, Q. (2025) · International Journal of Surgery · doi:10.1097/js9.0000000000004126 · Cited by 1
A framework to evaluate surrogate endpoints at the trial level: analysis in colorectal cancer
Chia, B. J., Allegra, C. J., Krishnamurthi, S., Lieu, C. H., Loree, J. M., & Shi, Q. Q. (2026) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djag088 · Cited by 1
High KPNA2 expression predicts poor prognosis in pathological T4 colorectal cancer by importing c-Myc into the nucleus to suppress p53-dependent p21 expression
Dorjkhorloo, G., Erkhem‐Ochir, B., Shiraishi, T., Okami, H., Yamaguchi, A., Shioi, I., Hosoi, N., Komine, C., Nakazawa, N., Shibasaki, Y., et al. (2026) · British Journal of Cancer · doi:10.1038/s41416-026-03552-5 · Cited by 1
Highlights From: 40th Annual Meeting of the American Society of Clinical Oncology; New Orleans, LA June 2004
Lee, D. J., Reddy, G. K., Ulfers, A. L., Chu, E., & Jain, V. K. (2004) · Clinical Colorectal Cancer · doi:10.1016/s1533-0028(11)70112-8 · Cited by 1
Individual data pooled analyses to improve understanding of adjuvant therapy in colon cancer: Review of the ACCENT collaborative group
Gill, S., & Sargent, D. J. (2008) · Current Colorectal Cancer Reports · doi:10.1007/s11888-008-0025-y · Cited by 1
Adjuvant therapy in colon cancer: which treatment in 2005?
Costanzo, F. D., & Doni, L. (2005) · Annals of Oncology · doi:10.1093/annonc/mdi911 · Cited by 1
End Points in Lung Cancer Clinical Trials: Are we Ready to Step Away from Overall Survival?
Mandrekar, S. J. (2013) · Lung Cancer Management · doi:10.2217/lmt.13.54 · Cited by 1
Discussion Contribution to 091037PR4 (Ghosh, Taylor, and Sargent)
Molenberghs, G. (2011) · Biometrics · doi:10.1111/j.1541-0420.2011.01634.x · Cited by 1
The effect of using combination chemotherapy in colorectal cancer in India: A single institute survey
Adiga, S., Kumari, K., Bairy, K., Amberkar, M. B., Vadhiraja, B., & Vidyasagar, V. (2009) · The Journal of Cancer Research · doi:10.5897/jcreo.9000026 · Cited by 1
Treatment Decisions and Medical Treatment of Cancer in Elderly Patients
Wedding, U., & Lichtman, S. M. (2012) · Springer eBooks · doi:10.1007/978-3-7091-0912-0_18 · Cited by 1
Statistical aspect of translational and correlative studies in clinical trials.
Pang, H., & Wang, X. (2016) · PubMed · doi:10.3978/j.issn.2304-3865.2014.07.04 · Cited by 1
“Analogous to surrogate clinical endpoints (5), surrogate biomarkers can be used as intermediate indicators of treatment efficacy in cancer treatment studies.”
Background
Validation of Patients with Stage III Colon Cancer According to the TNM, 7th Edition
Watanabe, A., Saitou, S., Hashimoto, Y., Kagawa, H., Bekku, E., Tomioka, H., Shiomi, A., & Kinugasa, Y. (2010) · Nihon Daicho Komonbyo Gakkai Zasshi · doi:10.3862/jcoloproctology.64.6 · Cited by 1
Surveillance and Follow-up
Hueman, M. T., & Ahuja, N. (2010) · Elsevier eBooks · doi:10.1016/b978-1-4160-4686-8.50022-1 · Cited by 1
Survival analysis in rectal carcinoma after neoadjuvant chemoradiation: various methods with different results
Merkel, S., Weber, K., Göhl, J., Agaimy, A., Fietkau, R., Hohenberger, W., Grützmann, R., & Hermanek, P. (2017) · International Journal of Colorectal Disease · doi:10.1007/s00384-017-2861-1 · Cited by 1
Evaluation of Surrogate Endpoints Using a Meta-Analysis Approach with Individual Patient Data: Summary of a Gastric Cancer Meta-Analysis Project
Oba, K., & Paolettí, X. (2017) · Springer eBooks · doi:10.1007/978-981-10-0126-0_12 · Cited by 1
Capecitabine and Oxaliplatin versus 5-Fluorouracil in the Neoadjuvant Chemoradiation for Patients with Locally Advanced Rectal Carcinoma: A Comparative Study
Rayan, A., Hasan, H. A., Zahran, A. M., Soliman, A. S. A., & Rezk, K. (2018) · Journal of Cancer Therapy · doi:10.4236/jct.2018.910063 · Cited by 1
Long-term Oncologic Outcomes After Curative Surgery in Stage I–III Thai Colorectal Cancer Patients
Mongkhonsupphawan, A., Sethalao, N., & Riansuwan, W. (2022) · Siriraj Medical Journal/San Sirirat · doi:10.33192/smj.2022.87 · Cited by 1
Impact of regional lymph node metastasis on pulmonary metastasis as the first recurrence site
Sueda, T., Tei, M., Yasuyama, A., Nomura, M., Yoshikawa, Y., Miyagaki, H., Tsujie, M., & Akamaru, Y. (2023) · Updates in Surgery · doi:10.1007/s13304-023-01633-1 · Cited by 1

Authors: Sargent, D. J., Wieand, H. S., Haller, D. G., Gray, R., Benedetti, J. K., Buyse, M., Labianca, R., Seitz, J. F., O'Callaghan, C. J., Francini, G., Grothey, A., O'Connell, M., Catalano, P. J., Blanke, C. D., Kerr, D., Green, E., Wolmark, N., Andre, T., Goldberg, R. M., & De Gramont, A.
Affiliations: University of Siena (IT)
From the North Central Cancer Treatment Group, Mayo Clinic, Rochester, MN; National Surgical Adjuvant Breast and Bowel Project Statistical Center and Operations Office, Pittsburgh; Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA; QUASAR Collaborative Group, Birmingham and Oxford, United Kingdom; Southwest Oncology Group Statistical Center, Seattle, WA; International Drug Development Institute, Brussels, Belgium; Ospedali Riuniti, Bergamo; University of Siena, Siena, Italy; University...
ORCID: Sargent, Daniel J.
Haller, Daniel G.
Gray, Richard
Buyse, Marc
Labianca, Roberto
Grothey, Axel
Catalano, Paul J.
Blanke, Charles D.
Kerr, David
Green, Erin
Wolmark, Norman
Goldberg, Richard M.
Venue: Journal of Clinical Oncology
Publisher: American Society of Clinical Oncology (ASCO)
Published: 2005-12-01
Volume: 23
Issue: 34
Pages: 8664-8670
ISSN: 0732-183X (ISSN-L)
1527-7755
DOI: 10.1200/jco.2005.01.6071
OpenAlex: W2172116130
Cited by: 713
References: 34
Citations by year: 2026: 19 · 2025: 14 · 2024: 19 · 2023: 20 · 2022: 34 · 2021: 32 · 2020: 27 · 2019: 20 · 2018: 24 · 2017: 30 · 2016: 26 · 2015: 40 · 2014: 36 · 2013: 40 · 2012: 44
FWCI: 48.43
Type: journal article
Language: en
Open access: closed
Locations: Journal of Clinical Oncology (publishedVersion)
PubMed (publishedVersion)
Document Server@UHasselt (UHasselt) (submittedVersion)
University of Birmingham Research Portal (University of Birmingham) (submittedVersion)
Use Siena air (University of Siena) (submittedVersion)
Funders: National Cancer Institute ((CA-25224, U10CA025224)
Topics: Physical Sciences › Mathematics › Statistics and Probability › Statistical Methods in Clinical Trials
Health Sciences › Medicine › Oncology › Colorectal Cancer Treatments and Studies
Health Sciences › Medicine › Oncology › Colorectal Cancer Surgical Treatments
Keywords: colon cancer, adjuvant chemotherapy, disease-free survival, overall survival, primary endpoint, surrogate endpoints, hazard ratio correlation, recurrence, individual patient data pooling
MeSH terms: Aged, Antineoplastic Combined Chemotherapy Protocols, Colonic Neoplasms, Combined Modality Therapy, Female, Follow-Up Studies, Humans, Male, Middle Aged, Neoplasm Recurrence, Local, Regression Analysis, Randomized Controlled Trials as Topic, Treatment Outcome, Chemotherapy, Adjuvant, Disease-Free Survival

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Disease-Free Survival Versus Overall Survival As a Primary End Point for Adjuvant Colon Cancer Studies: Individual Patient Data From 20,898 Patients on 18 Randomized Trials

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks